
    
      This is an international, multicenter, event-driven, randomized, double-blind, parallel
      group, placebo-controlled study, evaluating the utility of SZC versus placebo to reduce the
      incidence of sudden cardiac death (SCD), stroke, and arrhythmia-related hospitalizations,
      interventions, and emergency department (ED) visits in participants on chronic hemodialysis
      with recurrent hyperkalemia.
    
  